Stem and progenitor cell therapy for pulmonary arterial hypertension: effects on the right ventricle (2013 Grover Conference Series)


In experimental animals and in patients with pulmonary arterial hypertension (PAH), a wide spectrum of structural and functional conditions is known that may be responsible for the switch of a state of “compensated” right ventricular (RV) hypertrophy to a state of RV failure. In recent years, therapy with differentiated cells, endothelial progenitor cells, and mesenchymal stem cells has been shown to cause partial or complete reversal of pathological characteristics of PAH. The therapeutic effects of stem or progenitor cell therapy are considered to be (1) paracrine effects from stem or progenitor cells that had engrafted in the myocardium (or elsewhere), by compounds that have anti-inflammatory, antiapoptotic, and proangiogenic actions and (2) unloading effects on the right ventricle due to stem or progenitor cell–induced decrease in pulmonary vascular resistance and decrease in pulmonary artery pressure.

Read the full article online


Experimental Organ and Tissue Transplantation and Grafting
Pulmonary Arterial Hypertension
Right Ventricle: Structure, Function and Dysfunction


Arnoud van der Laarse, Christa M. Cobbaert, Soban Umar

Published in:

Pulmonary Circulation Vol 5: No 1 cover image

March 2015

Pulmonary Circulation Vol 5: No 1

View this journal

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI